Kamran Zargar-Shoshtari1, Homayoun Zargar2, Yair Lotan3, Jay B Shah4, Bas W van Rhijn5, Siamak Daneshmand6, Philippe E Spiess1, Peter C Black7. 1. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2. Vancouver Prostate Centre, Vancouver, British Columbia, Canada. 3. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Department of Urology, MD Anderson Cancer Center, Houston, Texas. 5. Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 6. USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, California. 7. Vancouver Prostate Centre, Vancouver, British Columbia, Canada. Electronic address: pblack@mail.ubc.ca.
Abstract
PURPOSE: Selected patients with bladder cancer with pelvic lymphadenopathy (cN1-3) are treated with induction chemotherapy followed by radical cystectomy. However, the data on clinical outcomes in these patients are limited. In this study we assess pathological and survival outcomes in patients with cN1-3 disease treated with induction chemotherapy and radical cystectomy. MATERIALS AND METHODS: Data were collected on patients from 19 North American and European centers with cT1-4aN1-N3 urothelial carcinoma who received chemotherapy followed by radical cystectomy between 2000 and 2013. The primary end points were pathological complete (pT0N0) and partial (pT1N0 or less) response rates, with overall survival as a secondary end point. Logistic regression and Cox proportional hazard ratios were used for multivariate analysis of factors predicting these outcomes. RESULTS: The total of 304 patients had clinical evidence of lymph node involvement (cN1-N3). Methotrexate/vinblastine/doxorubicin/cisplatin was used in 128 (42%), gemcitabine/cisplatin in 132 (43%) and other regimens in 44 (15%) patients. The pN0 rate was 48% (cN1-56%, cN2-39%, cN3-39%, p=0.03). The complete and partial pathological response rates for the entire cohort were 14.5% and 27%, respectively. The estimated median overall survival time for the cohort was 22 months (IQR 8.0, 54). On Cox regression analysis overall survival was associated with pN0, negative surgical margins, removal of 15 or more pelvic nodes and cisplatin therapy. CONCLUSIONS: Complete pathological nodal response can be achieved in a proportion of patients with cN1-3 disease receiving induction chemotherapy. The best survival outcomes are observed in male patients on cisplatin regimens with subsequent negative radical cystectomy margins and complete nodal response (pN0) with excision of 15 or more pelvic nodes.
PURPOSE: Selected patients with bladder cancer with pelvic lymphadenopathy (cN1-3) are treated with induction chemotherapy followed by radical cystectomy. However, the data on clinical outcomes in these patients are limited. In this study we assess pathological and survival outcomes in patients with cN1-3 disease treated with induction chemotherapy and radical cystectomy. MATERIALS AND METHODS: Data were collected on patients from 19 North American and European centers with cT1-4aN1-N3 urothelial carcinoma who received chemotherapy followed by radical cystectomy between 2000 and 2013. The primary end points were pathological complete (pT0N0) and partial (pT1N0 or less) response rates, with overall survival as a secondary end point. Logistic regression and Cox proportional hazard ratios were used for multivariate analysis of factors predicting these outcomes. RESULTS: The total of 304 patients had clinical evidence of lymph node involvement (cN1-N3). Methotrexate/vinblastine/doxorubicin/cisplatin was used in 128 (42%), gemcitabine/cisplatin in 132 (43%) and other regimens in 44 (15%) patients. The pN0 rate was 48% (cN1-56%, cN2-39%, cN3-39%, p=0.03). The complete and partial pathological response rates for the entire cohort were 14.5% and 27%, respectively. The estimated median overall survival time for the cohort was 22 months (IQR 8.0, 54). On Cox regression analysis overall survival was associated with pN0, negative surgical margins, removal of 15 or more pelvic nodes and cisplatin therapy. CONCLUSIONS: Complete pathological nodal response can be achieved in a proportion of patients with cN1-3 disease receiving induction chemotherapy. The best survival outcomes are observed in male patients on cisplatin regimens with subsequent negative radical cystectomy margins and complete nodal response (pN0) with excision of 15 or more pelvic nodes.
Authors: Mark Warren; Michael Kolinsky; Christina M Canil; Piotr Czaykowski; Srikala S Sridhar; Peter C Black; Christopher M Booth; Wassim Kassouf; Libni Eapen; Som D Mukherjee; Normand Blais; Bernhard J Eigl; Eric Winquist; Naveen S Basappa; Scott A North Journal: Can Urol Assoc J Date: 2019-04-26 Impact factor: 1.862
Authors: Andrea Necchi; Luigi Mariani; Salvatore Lo Vullo; Evan Y Yu; Michael E Woods; Yu-Ning Wong; Lauren C Harshman; Ajjaj Alva; Cora N Sternberg; Aristotelis Bamias; Petros Grivas; Vadim S Koshkin; Florian Roghmann; Jakub Dobruch; Bernie J Eigl; Lucia Nappi; Matthew I Milowsky; Guenter Niegisch; Sumanta K Pal; Ugo De Giorgi; Federica Recine; Ulka Vaishampayan; Dominik D Berthold; Daniel W Bowles; Jack Baniel; Christine Theodore; Sylvain Ladoire; Sandy Srinivas; Neeraj Agarwal; Simon Crabb; Srikala Sridhar; Ali-Reza Golshayan; Carsten Ohlmann; Evanguelos Xylinas; Thomas Powles; Johnathan E Rosenberg; Joaquim Bellmunt; Bas van Rhijn; Matthew D Galsky; Kees Hendricksen Journal: Eur Urol Focus Date: 2017-06-03
Authors: Homayoun Zargar; Jay B Shah; Elisabeth E Fransen van de Putte; Kylea R Potvin; Kamran Zargar-Shoshtari; Bas W van Rhijn; Siamak Daneshmand; Jeff M Holzbeierlein; Philippe E Spiess; Eric Winquist; Simon Horenblas; Colin Dinney; Peter C Black; Wassim Kassouf Journal: World J Urol Date: 2017-06-17 Impact factor: 4.226
Authors: Marco Moschini; Agostino Mattei; Julian Cornelius; Shahrokh F Shariat; Paolo Dell'Oglio; Emanuele Zaffuto; Andrea Salonia; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Andrea Gallina Journal: World J Urol Date: 2018-01-24 Impact factor: 4.226
Authors: Roger Li; Janet E Baack Kukreja; Mohamed A Seif; Firas G Petros; Matthew T Campbell; Justin V Nguyen; Graciela M Nogueras González; Ashish M Kamat; Louis L Pisters; Colin P Dinney; Neema Navai Journal: World J Urol Date: 2019-03-12 Impact factor: 4.226
Authors: Matthew D Galsky; Kristian Stensland; John P Sfakianos; Reza Mehrazin; Michael Diefenbach; Nihal Mohamed; Che-Kai Tsao; Paolo Boffetta; Peter Wiklund; William K Oh; Madhu Mazumdar; Bart Ferket Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: E E Fransen van de Putte; E Vegt; L S Mertens; A Bruining; K Hendricksen; M S van der Heijden; S Horenblas; B W G van Rhijn Journal: Int Urol Nephrol Date: 2017-07-03 Impact factor: 2.370